Morningside Ventures Launches Adiso Therapeutics to Advance Novel Therapies for Inflammatory Diseases

/PRNewswire/ -- Morningside Ventures today announced the launch of Adiso Therapeutics, a clinical-stage biotechnology company advancing a pipeline of novel...

Related Keywords

Australia ,United States ,Ireland ,America ,Smith Kline ,Jason Dinges ,Bristol Myers Squibb ,Jason Finkelstein ,Cothera Bioscience ,Mustafaa Noor ,Asia Pacific ,Jennifer Locke ,Sarah Sutton Liza Sullivan ,Scott Megaffin ,Linkedin ,University College Cork ,University Of Massachusetts Chan Medical School ,Schering ,Adastra Pharmaceuticals ,Pfizer ,University Of Edinburgh Centre For Inflammation Research ,Adiso Therapeutics Inc ,Microbiome Institute ,Morningside Technology Advisory ,Adiso Therapeutics ,Investigational New Drug ,Track Designation ,Chief Executive Officer ,Adiso Board ,Chief Medical Officer ,Akcea Therapeutics ,Glaxo Smith Kline ,Bristol Myers ,Massachusetts Chan Medical School ,Hudson Institute ,Medical Sciences Centre ,Innate Immunity ,Infectious Diseases ,Edinburgh Centre ,Fast Track Designation ,Morningside Ventures ,North America ,Chief Operations ,